Low interim influenza vaccine effectiveness, Australia, 1 May to 24 September 2017
Sheena G. Sullivan(The University of Melbourne), Monique Chilver(The University of Adelaide), Kylie Carville(Victorian Infectious Diseases Reference Laboratory), Yi‐Mo Deng(Victorian Infectious Diseases Reference Laboratory), Kristina A Grant(Victorian Infectious Diseases Reference Laboratory), Geoff Higgins(South Australia Pathology), Naomi Komadina(Victorian Infectious Diseases Reference Laboratory), Vivian Leung(Victorian Infectious Diseases Reference Laboratory), Cara Minney‐Smith(Pathwest Laboratory Medicine), Don Teng(Monash University), Thomas Tran(Victorian Infectious Diseases Reference Laboratory), Nigel Stocks(The University of Adelaide), James Fielding(The University of Melbourne)
Cited by 105Open Access
Abstract
In 2017, influenza seasonal activity was high in the southern hemisphere. We present interim influenza vaccine effectiveness (VE) estimates from Australia. Adjusted VE was low overall at 33% (95% confidence interval (CI): 17 to 46), 50% (95% CI: 8 to 74) for A(H1)pdm09, 10% (95% CI: -16 to 31) for A(H3) and 57% (95% CI: 41 to 69) for influenza B. For A(H3), VE was poorer for those vaccinated in the current and prior seasons.
Related Papers
No related papers found
Powered by citation graph analysis